Systemic therapies in hepatocellular carcinoma: Present and future

Future Oncology

Volumn 9, Issue 10, 2013, Pages 1533-1548

  Bertino, Gaetano ^a   Di Carlo, Isidoro ^a   Ardiri, Annalisa ^a   Calvagno, Giuseppe Stefano ^a   Demma, Shirin ^a   Malaguarnera, Giulia ^a   Bertino, Nicoletta ^a   Malaguarnera, Mariano ^a   Toro, Adriana ^a   Malaguarnera, Michele ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

antiangiogenic drugs; hepatocellular carcinoma; mmunotherapy; molecular hepatocarcinogenesis; sorafenib; sunitinib; targeted therapy; tivantinib

Indexed keywords

ALANINE AMINOTRANSFERASE; ANGIOGENESIS INHIBITOR; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; BRIVANIB; CABOZANTINIB; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; DENDRITIC CELL VACCINE; ERLOTINIB; FLUOROURACIL; GEMCITABINE; INTERLEUKIN 12; LINIFANIB; PLACEBO; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TIVANTINIB;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTIANGIOGENIC THERAPY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CHEMOEMBOLIZATION; CHILD PUGH SCORE; DECREASED APPETITE; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS VARICES; FATIGUE; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HEMATOLOGICAL TOXICITY; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTENSION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LOSS OF APPETITE; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NATURAL KILLER CELL; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SYSTEMIC THERAPY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING;

EID: 84885796029     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.171     Document Type: Review

References (123)

1. Lin CL, Kao JH. Risk stratification for hepatitis B virus related hepatocellular carcinoma. J. Gastroenterol. Hepatol. 28(1), 10-17 (2013)
2. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J. Gastroenterol. 44(Suppl. 19), 102-107 (2009)
3. Davila JA, Kramer JR, Duan Z et al. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and non-patient factors. Hepatology 57(5), 1858-1868 (2013)
4. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J. Hepatology 56(6), 1384-1391 (2012)
5. Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Galvagno GS. Hepacellular carcinoma serum markers. Semin. Oncol. 39(4), 410-433 (2012)
6. Bertino G, Neri S, Bruno CM et al. Diagnostic and prognostic value of alpha-fetoprotein, des-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma. Minerva Med. 102, 363-371 (2011)
7. nn Provides information about the diagnostic and prognostic assessment of old and new hepatocellular carcinoma (HCC) biomarkers
8. Bertino G, Ardiri AM, Calvagno GS et al. Prognostic and diagnostic value of des-g-carboxy prothrombin in liver cancer. Drug News Perspect. 23(8), 498-508 (2010)
9. Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 65, 6245-6254 (2005) (Pubitemid 40994410)
10. Biondi A, Malaguarnera G, Vacante M et al. Elevated serum levels of chromogranin A in hepatocellular carcinoma. BMC Surg. 12(Suppl. 1) S7 (2012)
11. Llovet JM, Brù C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 19(3), 329-338 (1999)
12. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J. Hepatol. 48 (Suppl. 1) S20-S37 (2008)
13. Giunchedi P, Maestri M, Gavini E, Dionigi P, Rassu G. Transarterial chemoembolization of hepatocellular carcinoma - agents and drugs: an overview. Part 2. Expert Opin. Drug Deliv. 10(6), 799-810 (2013)
14. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Aliment Pharmacol. Ther. 23, 1535-1547 (2006) (Pubitemid 43727460)
15. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 11, 790-800 (2006) (Pubitemid 44157567)
16. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin. Liver Dis. 27, 55-76 (2007)
17. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008)
18. Tanaka S, Arii S. Molecular targeted therapies in hepatocellular carcinoma. Semin. Oncol. 39(4), 486-492 (2012). n Provides information about molecular signaling in HCC
19. Zhou Q, Lui VW, Yeo W. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Review. Future Oncol. 8(1), 112 (2012)
20. Wörns MA, Weinmann A, Schuchmann M, Galle PR. Systemic therapies in hepatocellular carcinoma. Dig. Dis. 27(2), 175-188 (2009)
21. Huang C, Xu D, Xia Q, Wang P, Rong C, Su Y. Reversal of P-glycoprotein-mediated multidrug resistance of human hepatic cancer cells by Astragaloside II. J. Pharm. Pharmacol. 64(12), 1741-1750 (2012)
22. Chen MC, Chen CH, Chuang HC, Kulp SK, Teng CM, Chen CS. Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIa degradation in hepatocellular carcinoma cells. Hepatology 53(1), 148-159 (2011)
23. Yau T, Chan P, Epstein R, Poon RT. Evolution of systemic therapy of advanced hepatocellular carcinoma. World J. Gastroenterol. 14, 6437-6441 (2008)
24. Verhoef C, van Dekken H, Hofland LJ et al. Somatostatin receptor in human hepatocellular carcinomas: biological, patient and tumor characteristics. Dig. Surg. 25, 21-26 (2008) (Pubitemid 351560591)
25. Becker S, Ardisson V, Lepareur N et al. Increased Lipiodol uptake in hepatocellular carcinoma possibly due to increased membrane fluidity by dexamethasone and tamoxifen. Nucl. Med. Biol. 37(7), 777-784 (2010)
26. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 53, 1020-1022 (2011)
27. Ng SA, Lee C. Hepatitis B virus X gene and hepatocarcinogenesis. J. Gastroenterol. 46(8), 974-990 (2011)
28. Miroux C, Vausselin T, Delhem N. Regulatory T cells in HBV and HCV liver diseases: implication of regulatory T lymphocytes in the control of immune response. Expert Opin. Biol. Ther. 10, 1563-1572 (2010)
29. Petrovic D, Stamataki Z, Dempsey E et al. Hepatitis C virus targets the T cell secretory machinery as a mechanism of immune evasion. Hepatology 53(6), 1846-1853 (2011)
30. Villanueva A, Toffanin S, Llovet JM. Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr. Opin. Oncol. 20, 444-453 (2008)
31. Boyault S, Rickman DS, de Reynies A et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45, 42-52 (2007) (Pubitemid 46144363)
32. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin. Liver Dis. 27, 55-76 (2007)
33. Huynh H, Nguyen TT, Chow KH, Tan PH, Soo KC, Tran E. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol. 3, 19 (2003)
34. Desai MD, Saroya BS, Lockhart AC. Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers. Expert Opin. Investig. Drugs 22(3), 341-356 (2013)
35. Goyal L, Muzumdar MD, Zhu AX. Targeting the HGF/c-MET Pathway in hepatocellular carcinoma. Clin. Cancer Res. 19(9), 2310-2318 (2013)
36. Chao Y, Li CP, Chau GY et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann. Surg. Oncol. 10, 355-362 (2003) (Pubitemid 40486931)
37. Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br. J. Surg. 91, 1354-1360 (2004) (Pubitemid 39331462)
38. Epstein RJ. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic. Cancer Metastasis Rev. 26, 443-452 (2007) (Pubitemid 350115101)
39. Saxena NK, Sharma D, Ding X et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 67, 2497-2507 (2007) (Pubitemid 46548934)
40. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48, 1312-1327 (2008)
41. Bertino G, Ardiri AM, Boemi PM et al. A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma. Panminerva Med. 50(3), 221-226 (2008)
42. Ishiguro T, Sugimoto M, Kinoshita Y et al. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res. 68, 9832-9838 (2008)
43. Piao W, Wang Y, Adachi Y et al. Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas. Mol. Cancer Ther. 7, 1483-1493 (2008)
44. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92, 205-216 (2000)
45. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad-spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004) (Pubitemid 39331023)
46. Liu L, Cao Y, Chen C et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66, 11851-11858 (2006) (Pubitemid 46094197)
47. Zhu AX. Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)? BMC Med. 7, 42 (2009)
48. Wilhelm SM, Adnane L, Newell P et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7, 3129-3140 (2008)
49. Chen KF, Tai WT, Liu TH et al. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin. Cancer Res. 16(21), 5189-5199 (2010)
50. Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother. Pharmacol. 61, 535-548 (2008)
51. Xie B, Wang DH, Spechler SJ. Sorafenib for treatment of hepatocellular carcinoma: a systematic review. Dig. Dis. Sci. 57, 1122-1129 (2012)
52. Furuse J, Ishii H, Nakachi K et al. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci. 99, 159-165 (2008) (Pubitemid 350239045)
53. Castroagudin JF, Molina E et al. Short-term efficacy and safety of treatment of advanced hepatocellular carcinoma with sorafenib. J. Hepatol. 48, S141-S142 (2008)
54. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24, 4293-4300 (2006) (Pubitemid 46630787)
55. Massa E, Spiga C, Chessa L et al. Efficacy, safety and impact on quality of life of a treatment with sorafenib in elderly cancer patients with advanced hepatocellular carcinoma. Result of a Phase II study. Ann. Oncol. 20, S65 (2009)
56. Yau T, Chan P, Ng KK et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 115, 428-436 (2009)
57. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Ppacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25-34 (2009)
58. Di Costanzo GG, Tortora R, Iodice L et al. Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice. Dig. Liver Dis. 44(9), 788-792 (2012)
59. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 30, 52-60 (2010)
60. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25-34 (2009)
61. Sprinzl MF, Reisinger F, Puschnik A et al. Sorafenib perpetuates cellular anti-cancer effector functions by modulating the cross talk between macrophages and natural killer cells. Hepatology 57(6), 2358-2368 (2013)
62. Yau T, Chan P, Cheung FY et al. Phase II trial of sorafenib with capecitabine and oxaliplatin (SECOX) in patients with locally advanced or metastatic hepatocellular carcinoma. EJC 7(3), 20-21 (2009)
63. Abou-Alfa GK, Johnson P, Knox JJ et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 304, 2154-2160 (2010)
64. Hsu CH, Shen YC, Lin ZZ et al. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J. Hepatol. 53, 126-131 (2010). n Phase I and II studies on sorafenib alone/combination treatment
65. Giuliani F, Febbraro A, Addeo R et al. Sorafenib plus cisplatin and gemcitabine in the treatment of advanced hepatocellular carcinoma: a Phase II study by the Gruppo Oncologico Italia Meridionale (PROT. GOIM 2705). Cancer Treat. Rev. 36, S96 (2010)
66. Erhardt A, Kolligs F, Dollinger M et al. First-in-men demonstration of sorafenib plus TACE for the treatment of advanced hepatocellular carcinoma (SOCRATES trial). Hepatology 50, 1080A (2009)
67. Reyes D, Azad N, Kamel I et al. Phase II trial of sorafenib with doxorubicin eluting bead-transarterial chemoembolization (DEB-TACE) for patients with hepatocellular carcinoma: interim safety and efficacy analysis. Hepatology 50, 6A-7A (2009)
68. Finn RS. Overview and description of hepatocellular carcinoma. Clin. Adv. Hematol. Oncol. 5(4), 4-7 (2013)
69. Kelley RK, Venook AP. Novel therapeutics in hepatocellular carcinoma. Am. Soc. Clin. Oncol. Educ. Book 2013, 137-142 (2013)
70. Wörns MA, Schuchmann M, Düber C, Otto G, Galle PR, Weinmann A. Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. Oncology 79(1-2), 85-92 (2010)
71. Kefeli U, Buyukberber S, Akyol M et al. Efficacy of sunitinib in Turkish patients with gastrointestinal stromal tumors; retrospective multicenter experience. Hepatogastroenterology 60(124), 647-652 (2012)
72. Zhu AX, Sahani DV, di Tomaso E et al. Sunitinib monotherapy in patients with advanced heaptocellular carcinoma: insights from a multidisciplinary Phase II study. J. Clin. Oncol. 26(Suppl. 15), Abstract 4521 (2008)
73. Hoda D, Catherine C, Strosberg J et al. Phase II study of sunitinib malate in adult patients with metastatic or surgically unresectable hepatocellular carcinoma. Gastrointestinal Cancers Symposium 4(4), Abstract 267 (2008)
74. Huynh H, Choo SP, Toh HC et al. Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation. Curr. Cancer Drug Targets 11(8), 944-953 (2011)
75. Bagi CM, Gebhard DF, Andresen CJ. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 24(5), 563-574 (2012)
76. Toh HC, Chen PJ, Carr BI et al. Phase II trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer 119(2), 380-387 (2013)
77. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer 12, 89-103 (2012)
78. Munshi N, Jeay S, Li Y et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol. Cancer Ther. 9, 1544-1553 (2010)
79. Previdi S, Abbadessa G, Dalo F, France DS, Broggini M. Breast cancer-derived bone metastasis can be eff ectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown. Mol. Cancer Ther. 11, 214-223 (2012)
80. Yap TA, Olmos D, Brunetto AT et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J. Clin. Oncol. 29, 1271-1279 (2011)
81. Martell RE, Puzanov I, Ma WW et al. Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a Phase I study. Proc. Am. Soc. Clin. Oncol. 30(Suppl.), Abstract 4117 (2012)
82. Santoro A, Rimassa L, Borbath I et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled Phase 2 study. Lancet Oncol. 14(1), 55-63 (2013)
83. nn Important study about tivantinib
84. Trojan J, Zeuzem S. Tivantinib in hepatocellular carcinoma. Expert Opin. Investig. Drugs. 22(1), 141-147 (2013)
85. Santoro A, Simonelli M, Rodriguez-Lope C et al. A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. Br. J. Cancer 108(1), 21-24 (2013)
86. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004) (Pubitemid 38702844)
87. Epstein RJ. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic. Cancer Metastasis Rev. 26(3), 443-452 (2007) (Pubitemid 350115101)
88. Siegel AB, Cohen EI, Ocean A et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J. Clin. Oncol. 26(18), 2992-2998 (2008)
89. Zhu AX, Blaszkowsky LS, Ryan DP et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24(12), 1898-1903 (2006) (Pubitemid 46638989)
90. Sun W, Haller DG, Mykulowycz K et al. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer 117(14), 3187-3192 (2011)
91. Hsu C, Yang T, Hsu C et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br. J. Cancer 102(6), 981-986 (2010)
92. Kaseb AO, Garrett-Mayer E, Morris JS et al. Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a Phase II trial. Oncology 82(2), 67-74 (2012)
93. Fang P, Hu JH, Cheng ZG, Liu ZF, Wang JL, Jiao SC. Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of Phase II trials. PLoS One 7(12), e49717 (2012)
94. Hsu CH, Yang TS, Hsu C et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br. J. Cancer 102, 981-986 (2010)
95. Sun W, Sohal D, Haller DG et al. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer 117, 3187-3192 (2011)
96. Thomas MB, Morris JS, Chadha R et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J. Clin. Oncol. 27, 843-850 (2009)
97. Yau T, Wong H, Chan P et al. Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease. Invest. New Drugs 30(6) 2384-2390 (2012)
98. Philip PA, Mahoney MR, Holen KD et al. Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer. Cancer 118, 2424-2430 (2012)
99. Chou T, Finn RS. Brivanib: a review of development. Future Oncol. 8(9), 1083-1090 (2012)
100. Finn RS, Kang YK, Mulcahy M et al. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 18(7), 2090-2098 (2012)
101. Zhu AX, Finn RS, Mulcahy MF et al. A Phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC). J. Clin. Oncol. 28(Suppl. 15), 4083 (2010)
102. Verslype C, Cohn AL, Kelley RK et al. Activity of cabozantinib (XL184) in hepatocellular carcinoma: results from a Phase 2 randomized discontinuation trial (RDT). J. Clin. Oncol. 30(Suppl.), Abstract 4007 (2012)
103. Teramoto K, Ohshio Y, Fujita T, Hanaoka J, Kontani K. Simultaneous activation of T helper function can augment the potency of dendritic cell-based cancer immunotherapy. J. Cancer Res. Clin. Oncol. 139(5), 861-870 (2013)
104. Zhong JH, Ma L, Wu LC et al. Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review. Int. J. Clin. Pract. 66(1), 21-27 (2012)
105. d'Onofrio A. Multifaceted kinetics of immuno-evasion from tumor dormancy. Adv. Exp. Med. Biol. 734, 111-143 (2013)
106. Fagnoni FF, Zerbini A, Pelosi G, Missale G. Combination of radiofrequency ablation and immunotherapy. Front. Biosci. 13, 369-381 (2008) (Pubitemid 351594784)
107. O'Bryan JM, Potts JA, Bonkovsky HL, Mathew A, Rothman AL. Extended interferon-alpha therapy accelerates telomere length loss in human peripheral blood T lymphocytes. PLoS One 6(8), e20922 (2011)
108. Pardee AD, Butterfield LH. Immunotherapy of hepatocellular carcinoma: unique challenges and clinical opportunities. Oncoimmunology 1(1), 48-55 (2012)
109. Stroffolini T, Spadaro A, Di Marco V et al. Current practice of chronic hepatitis B treatment in southern Italy. Eur. J. Intern. Med. 23(5), e124-e127 (2012)
110. Zhao F, Korangy F, Greten TF. Cellular immune suppressor mechanisms in patients with hepatocellular carcinoma. Dig. Dis. 30(5), 477-482 (2012)
111. Cai L, Zhang Z, Zhou L et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin. Immunol. 129, 428-437 (2008)
112. Takayama T, Sekine T, Makuuchi M et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356, 802-807 (2000)
113. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J. Immunother. 28, 496-504 (2005)
114. Kayashima H, Toshima T, Okano S et al. Intratumoral neoadjuvant immunotherapy using IL-12 and dendritic cells is an effective strategy to control recurrence of murine hepatocellular carcinoma in immunosuppressed mice. J. Immunol. 185, 698-708 (2010)
115. Schmidt N, Neumann-Haefelin C, Thimme R. Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy. Dig. Dis. 30(5), 483-491(2012). nn New immunological-based targets in HCC treatment
116. El Ansary M, Mogawer S, Elhamid SA et al. Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC. Cancer Res. Clin. Oncol. 139(1), 39-48 (2013)
117. Mizukoshi E, Nakamoto Y, Arai K et al. Comparative analysis of various tumor-associated antigen-specific T-cell responses in patients with hepatocellular carcinoma. Hepatology 53, 1206-1216 (2011)
118. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore antitumorimmunity. J. Exp. Med. 207, 2187-2194 (2010)
119. Pardee AD, McCurry D, Alber S, Hu P, Epstein AL, Storkus WJ. A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. Cancer Res. 70, 9041-9052 (2010)
120. Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat. Rev. Clin. Oncol. 8, 292-301(2011)
121. Heo J, Reid T, Ruo L et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med. 19, 329-336 (2013)
122. Ang C, O'Reilly EM, Abou-Alfa GK. Targeted agents and systemic therapy in hepatocellular carcinoma. Recent Results Cancer Res. 190, 225-246 (2013)
123. Malaguarnera G, Paladina I, Giordano M, Malaguarnera M, Bertino G, Berretta M. Serum markers of intrahepatic cholangiocarcinoma. Dis Markers 34(4), 219-228 (2013).